ISDA

Deposition Date 2017-07-10

Release Date 2017-09-06

Last Version Date 2024-11-13

Entry Detail

PDB ID:

5WEV

Keywords:

Transferase/Transferase Inhibitor

Title:

Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

unidentified baculovirus

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.85 Å

R-Value Free:

0.19

R-Value Work:

0.16

R-Value Observed:

0.16

Space Group:

C 1 2 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Tyrosine-protein kinase JAK2
Gene (Uniprot):JAK2
Chain IDs:A
Chain Length:319
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:O60674 Pfam ID:PF07714 EC:2.7.10.2

Modified Residue

Compound ID	Chain ID	Parent Comp ID	Details	2D Image
PTR	A	TYR	modified residue

Ligand Molecules

9ZS

Primary Citation

Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model.

Liang, J, Van Abbema, A, Balazs, M, Barrett, K, Berezhkovsky, L, Blair, W.S, Chang, C, Delarosa, D, DeVoss, J, Driscoll, J, Eigenbrot, C, Goodacre, S, Ghilardi, N, MacLeod, C, Johnson, A, Bir Kohli, P, Lai, Y, Lin, Z, Mantik, P, Menghrajani, K, Nguyen, H, Peng, I, Sambrone, A, Shia, S, Smith, J, Sohn, S, Tsui, V, Ultsch, M, Williams, K, Wu, L.C, Yang, W, Zhang, B, Magnuson, S.Show

Bioorg. Med. Chem. Lett. 27 4370 4376 (2017)

PMID: 28830649 DOI: 10.1016/j.bmcl.2017.08.022

Abstact

Herein we report identification of an imidazopyridine class of potent and selective TYK2 inhibitors, exemplified by prototype 6, through constraint of the rotatable amide bond connecting the pyridine and aryl rings of compound 1. Further optimization led to generation of compound 30 that potently inhibits the TYK2 enzyme and the IL-23 pathway in cells, exhibits selectivity against cellular JAK2 activity, and has good pharmacokinetic properties. In mice, compound 30 demonstrated dose-dependent reduction of IL-17 production in a PK/PD model as well as in an imiquimod-induced psoriasis model. In this efficacy model, the IL-17 decrease was accompanied by a reduction of ear thickness indicating the potential of TYK2 inhibition as a therapeutic approach for psoriasis patients.

Legend

Protein

Chemical

Disease

Primary Citation of related structures